Print

---

Dear Linda,

Perhaps you could advise me.... I cannot grasp an understanding of your
letter as it clearly is aimed at those in the medical profession with
knowledge of the  terminology used. This is fine but I am a Parkinson's
sufferer and would appreciate access to a lay explanation of matters
WRT Parkinson's and information concerning my expectations for the
future.

Can you advise me here. I have a reasonable level of intelligence so
please don't oversimplify. I have just turned 60 and was diagnosed
about three years ago.

Sincerely,

Leigh Wayper

On 09/01/2005, at 9:22 PM, Linda J Herman wrote:

> FROM:   Medical Letter on the CDC & FDA
>  January 9, 2005
>
> SECTION: EXPANDED REPORTING; Pg. 94
>
> HEADLINE: PARKINSON DISEASE;
> Biotech firm gets NIH grant to study environmental causes of Parkinson
> disease
>
>     RxGen, Inc., a private biotechnology company, announced that the
> National
> Institutes of Health (NIH) has funded phase 1 of the company's Fast
> Track
> SBIR
> grant for $1.1 million to uncover genomic markers of Parkinson disease.
>
>     RxGen is using genomics and bioinformatics technologies and
> knowledge
> of
> primate models of Parkinson disease to profile in vivo brain RNA
> expression
> patterns following exposure to compounds known to cause the neuronal
> injury and
> dopamine depletion associated with Parkinson disease.
>
>     RxGen's plans to profile toxins such as rotenone,
> tetrahydroisoquinolone,
> dithiocarbamate, and Paraquat, which have been implicated as possible
> environmental causes of Parkinson disease. This grant will enable RxGen
> to
> examine critical pathways of injury and neuroprotection specific to
> dopaminergic
> neurons, which may set the stage for developing therapeutic
> interventions.
>
>     The NIH SBIR funding will help RxGen advance its internal research
> and
> development programs associated with predictive toxicology and central
> nervous
> system drug discovery. RxGen's predictive toxicology technology
> program,
> PrimaTox, was recently funded by the NIH through a separate Fast Track
> SBIR
> award of $1.4 million.
>
>     RxGen has access to a primate facility with 27 years of experience
> in
> research pertaining to Parkinson disease and other neurodegenerative
> conditions
> and related therapeutic strategies.
>
>     RxGen, Inc. is focused on the development of therapeutics for
> neurodegeneration, memory loss, obesity and other central nervous
> system
> disorders using animal models of human disease and leading genomics and
> bioinformatics.
>
>     This article was prepared by Medical Letter on the CDC  &  FDA
> editors from
> staff and other reports.  Copyright 2005, Medical Letter on the CDC  &
> FDA via
> NewsRx.com  &  NewsRx.net.
>
> ----------------------------------------------------------------------
> To sign-off Parkinsn send a message to:
> mailto:[log in to unmask]
> In the body of the message put: signoff parkinsn
>

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn